Table 1.
Preperty | Deferoxamine | Deferiprone | Deferasirox |
---|---|---|---|
Chelator: Fe | 1:1 | 3:1 | 2:1 |
Route of administration | Subcutaneous Intravenous Implantable delivery system |
Oral | Oral |
Usual dosage | 25–50 mg/kg/day | 75–100 mg/kg/day | 20–30 mg/kg/day |
Schedule | Administration overt 8–24 hours 5–7 days a week | 3× daily | Daily |
Half-life | Short (minutes) | Moderate (hours) | Long (8–46 hours) |
Adverse effects | Local reactions Retinal toxicity Auditory toxicity Pulmonary toxicity |
Agranulocytosis, with mild neutropenia Arthralgia/erosive arthritis |
Abdominal discomfort with rash or mild diarrhea; mild elevation in creatinine |
Monitoring | Hearing test Vision test Growth assessment Pulmonary function Renal function Liver Function |
CBC with differential Zinc Liver function |
CBC with differential Platelet count Liver function Renal function |
Advantages | Long-term data available | May be superior in removal of cardiac iron | Once daily dosage |
Abbreviation: CBC, complete blood count.